Synonym: Anti-AURA17, Anti-Dardarin, Anti-Leucine-rich repeat protein kinase 2, Anti-PARK8, Anti-RIPK7, Anti-ROCO2
Popular Documents: Datasheet (PDF)
| Related Categories | Alphabetical Index, Antibodies, Antibodies for Parkinson’s Disease Research, Antibodies in Array, Cell Biology, |
| species reactivity | mouse, rat, human |
| application(s) | western blot: 2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using rat and mouse brain extracts (S2 fraction) |
| clone | polyclonal |
| concentration | ~1.0 mg/mL |
| antibody form | affinity isolated antibody |
| form | buffered aqueous solution |
| mol wt | antigen mol wt ~240 kDa |
| shipped in | dry ice |
| storage temp. | −20°C |
| Gene Information |
human ... LRRK2(120892) mouse ... Lrrk2(66725) rat ... Lrrk2(300160) |
synthetic peptide corresponding to amino acids 2079-2100 of human LRRK2 conjugated to KLH. The corresponding sequence is highly conserved (single amino acid substitution) in mouse and rat LRRK2.
LRRK2 is a μLtimeric kinase that also functions as a GTPase. LRRK2 activates a CaMKK-β/AMPK signaling pathway and subsequently mediates autophagy. Genetic alterations in LRRK2 cause late-onset Parkinson′s disease 1,2. Anti-LRRK2 (C-terminal region) antibody is specific for LRRK2 (approx. 240 kDa) in mice, rats and humans. Staining of the LRRK2 band by immunoblotting is specifically inhibited by the LRRK2 immunizing peptide.
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Anti-LRRK2 (C-terminal region) antibody is suitable for use in western blot (2-4 μg/mL using HEK-293T cells expressing human LRRK2, and using S2 fractions of rat and mouse brain extracts).
Customers Also Viewed

Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?